Summary
Guardant Health, Inc. (GH) has filed an 8-K report on July 30, 2026, to announce its financial results for the fiscal quarter ended June 30, 2026. The primary purpose of this filing is to furnish the accompanying press release, which contains the detailed financial and operational performance for the period. Investors should refer to Exhibit 99.1, the press release itself, for the specific figures and management commentary regarding revenue, profitability, and key performance indicators. While the 8-K itself provides a formal notification of the release, the substantive information is contained within the press release. Investors are advised to carefully review this press release for insights into the company's top-line growth, cost management, and any forward-looking guidance provided by Guardant Health. This information is crucial for assessing the company's current financial health and future prospects within the competitive landscape of precision oncology.
Key Highlights
- 1Guardant Health, Inc. (GH) filed an 8-K on July 30, 2026, announcing Q2 2026 financial results.
- 2The press release (Exhibit 99.1) contains the detailed financial results and management discussion.
- 3Investors should consult the furnished press release for specific performance metrics.
- 4The filing is a standard notification of earnings release under Item 2.02.
- 5Information furnished is not deemed 'filed' for certain regulatory purposes, but is material to investors.
- 6The report includes the cover page interactive data file in Inline XBRL format.